When AbbVie issued its Q2 earnings warning for 2025, investors understandably got nervous. The company announced it would take a hit of $823 million to account for acquired in-process research and development (IPR&D) and milestone expenses. That translates to a $0.42 drag on earnings per share for the quarter. Wall Street doesn't exactly throw parties for surprise expenses that slash profits. But here's the kicker: while this may seem like a facepalm-worthy blunder, it's not the catastrophe many fear. In fact, it reflects a strategic—and arguably necessary—pivot in AbbVie's long-term growth plan. So yes, the R&D situation looks messy. But this isn't a fire drill. What Exactly Happened in Q2? Let’s break down the basics. AbbVie is adjusting its Q2 2025 earnings guidance downward due to a massive non-cash charge. The expense is related to recently acquired R&D assets and milestone payments from M&A activity, most notably its acquisition of Capstan Ther...